Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Exagen stock

Learn how to easily invest in Exagen stock.

Exagen Inc
NASDAQ: XGN - USD
$2.92
+ $0.08 ( + 2.82%)
DIAGNOSTICS & RESEARCH

Exagen Inc is a diagnostics & research business based in the US. Exagen shares (XGN) are listed on the NASDAQ and all prices are listed in US Dollars. Exagen employs 219 staff and has a trailing 12-month revenue of around $44.3 million.

How to buy shares in Exagen

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – XGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Exagen stock price (NASDAQ: XGN)

Use our graph to track the performance of XGN stocks over time.

Exagen shares at a glance

Information last updated 2022-10-04.
Latest market close$2.84
52-week range$2.65 - $14.85
50-day moving average $5.05
200-day moving average $6.89
Wall St. target price$12.25
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.82

Buy Exagen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Exagen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Exagen price performance over time

Historical closes compared with the close of $2.84 from 2022-10-05

1 week (2022-09-26) -8.39%
1 month (2022-09-02) N/A
3 months (2022-07-06) -54.92%
6 months (2022-04-05) -61.10%
1 year (2021-10-06) -78.19%
2 years (2020-10-06) -77.04%
3 years (2019-10-04) 14.55
5 years (2017-10-02) N/A

Exagen financials

Revenue TTM $44.3 million
Gross profit TTM $27.7 million
Return on assets TTM -18.23%
Return on equity TTM -47.1%
Profit margin -85.36%
Book value $3.95
Market capitalisation $44.1 million

TTM: trailing 12 months

Exagen share dividends

We're not expecting Exagen to pay a dividend over the next 12 months.

Exagen share price volatility

Over the last 12 months, Exagen's shares have ranged in value from as little as $2.65 up to $14.85. A popular way to gauge a stock's volatility is its "beta".

XGN.US volatility(beta: 1.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exagen's is 1.0294. This would suggest that Exagen's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Exagen overview

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.

Frequently asked questions

What percentage of Exagen is owned by insiders or institutions?
Currently 21.34% of Exagen shares are held by insiders and 77.573% by institutions.
How many people work for Exagen?
Latest data suggests 219 work at Exagen.
When does the fiscal year end for Exagen?
Exagen's fiscal year ends in December.
Where is Exagen based?
Exagen's address is: 1261 Liberty Way, Vista, CA, United States, 92081
What is Exagen's ISIN number?
Exagen's international securities identification number is: US30068X1037
What is Exagen's CUSIP number?
Exagen's Committee on Uniform Securities Identification Procedures number is: 30068X103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site